GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Navco Pharmaceuticals Inc (TSXV:NAV) » Definitions » Return-on-Tangible-Asset

Navco Pharmaceuticals (TSXV:NAV) Return-on-Tangible-Asset : 33.86% (As of Mar. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Navco Pharmaceuticals Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Navco Pharmaceuticals's annualized Net Income for the quarter that ended in Mar. 2023 was C$0.03 Mil. Navco Pharmaceuticals's average total tangible assets for the quarter that ended in Mar. 2023 was C$0.09 Mil. Therefore, Navco Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2023 was 33.86%.

The historical rank and industry rank for Navco Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:

TSXV:NAV' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -111.78   Med: -49.83   Max: -24.27
Current: -44.68

During the past 4 years, Navco Pharmaceuticals's highest Return-on-Tangible-Asset was -24.27%. The lowest was -111.78%. And the median was -49.83%.

TSXV:NAV's Return-on-Tangible-Asset is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.84 vs TSXV:NAV: -44.68

Navco Pharmaceuticals Return-on-Tangible-Asset Historical Data

The historical data trend for Navco Pharmaceuticals's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Navco Pharmaceuticals Return-on-Tangible-Asset Chart

Navco Pharmaceuticals Annual Data
Trend Jun18 Jun19 Jun20 Jun21
Return-on-Tangible-Asset
- -111.78 -24.27 -49.83

Navco Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.23 -168.61 -7.08 -23.08 33.86

Competitive Comparison of Navco Pharmaceuticals's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Navco Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Navco Pharmaceuticals's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Navco Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Navco Pharmaceuticals's Return-on-Tangible-Asset falls into.



Navco Pharmaceuticals Return-on-Tangible-Asset Calculation

Navco Pharmaceuticals's annualized Return-on-Tangible-Asset for the fiscal year that ended in Jun. 2021 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Jun. 2021 )  (A: Jun. 2020 )(A: Jun. 2021 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Jun. 2021 )  (A: Jun. 2020 )(A: Jun. 2021 )
=-0.074/( (0.181+0.116)/ 2 )
=-0.074/0.1485
=-49.83 %

Navco Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2023 )  (Q: Dec. 2022 )(Q: Mar. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2023 )  (Q: Dec. 2022 )(Q: Mar. 2023 )
=0.032/( (0.094+0.095)/ 2 )
=0.032/0.0945
=33.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2023) net income data.


Navco Pharmaceuticals  (TSXV:NAV) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Navco Pharmaceuticals Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Navco Pharmaceuticals's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Navco Pharmaceuticals (TSXV:NAV) Business Description

Traded in Other Exchanges
N/A
Address
1055 West Georgia Street, Suite 1500, Vancouver, BC, CAN, V6E 4N7
Website
Navco Pharmaceuticals Inc uses of nanotechnology to develop and commercialize novel products to protect against viruses, bacteria, and infectious diseases. The company's pipeline of applications is tailored to defend against pathogens utilizing new methods of action to capitalize on unmet product needs using natural & known compounds, nanoparticles, and no chemicals with a high degree of efficacy. Its target markets include human health & personal skin care, household & institutional products, and veterinary health.

Navco Pharmaceuticals (TSXV:NAV) Headlines

From GuruFocus

Navistar Stockholders Approve Acquisition by TRATON

By PRNewswire PRNewswire 03-03-2021

Navistar Shares Vision Of Opportunity For Service Technicians

By PRNewswire PRNewswire 02-09-2021